Advertisement
UK markets close in 1 hour 45 minutes
  • FTSE 100

    8,174.97
    +10.07 (+0.12%)
     
  • FTSE 250

    21,075.46
    -138.33 (-0.65%)
     
  • AIM

    786.14
    -0.84 (-0.11%)
     
  • GBP/EUR

    1.1912
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.3031
    +0.0058 (+0.44%)
     
  • Bitcoin GBP

    49,621.59
    +516.54 (+1.05%)
     
  • CMC Crypto 200

    1,343.23
    +0.91 (+0.07%)
     
  • S&P 500

    5,612.67
    -54.53 (-0.96%)
     
  • DOW

    40,988.18
    +33.70 (+0.08%)
     
  • CRUDE OIL

    82.04
    +1.28 (+1.58%)
     
  • GOLD FUTURES

    2,483.10
    +15.30 (+0.62%)
     
  • NIKKEI 225

    41,097.69
    -177.39 (-0.43%)
     
  • HANG SENG

    17,739.41
    +11.43 (+0.06%)
     
  • DAX

    18,440.27
    -77.76 (-0.42%)
     
  • CAC 40

    7,551.46
    -28.57 (-0.38%)
     

MDxHealth to Present Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

mdxhealth
mdxhealth

NEWS RELEASE
FEBRUARY 22, 2023, 4:30pm ET/ 22:30 CET

Company to Host Conference Call with Live Q&A, March 8, 2023 at 4:30pm ET/ 22:30 CET

IRVINE, CA, and HERSTAL, BELGIUM – February 22, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on Wednesday, March 8, 2023.

Title:

Mdxhealth Presents Fourth Quarter and Full Year 2022 Financial Results

Speakers:

Michael K. McGarrity, Chief Executive Officer
Ron Kalfus, Chief Financial Officer

Date:

Wednesday, March 8, 2023

Time:

4:30pm ET/ 22:30 CET

Conference Call Dial-in Details:



United States: 1-877-407-9716
Belgium: 0800 73904
The Netherlands: 0800 023 4340
United Kingdom: 0800 756 3429



Webcast:

https://viavid.webcasts.com/starthere.jsp?ei=1600322&tp_key=c5695c9654

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

ADVERTISEMENT

About mdxhealth®

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

mdxhealth

info@mdxhealth.com

 

LifeSci Advisors (IR & PR)
US: +1 949 271 9223
ir@mdxhealth.com

 

NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

Attachment